FindTrial
Sign In

Lorano akut

DRUG2 trials

Sponsors

ROXALL Medizin GmbH, ROXALL Medizin GmbH, ROXALL Medizin GmbH

Conditions

Moderate-to-severe allergic rhinitis / rhinoconjunctivitis due to birch pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelineModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to grass pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline

Phase 2

Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from birch pollen allergy
CompletedCTIS2023-505567-37-00
ROXALL Medizin GmbHModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to birch pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline
Start: 2023-08-22End: 2024-10-11Target: 30Updated: 2023-08-22
Phase II-III study to assess efficacy and safety of sublingual immunotherapy in patients suffering from grass pollen allergy
CompletedCTIS2023-505880-35-00
ROXALL Medizin GmbH, ROXALL Medizin GmbHModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to grass pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline
Start: 2023-11-10End: 2024-11-07Target: 30Updated: 2023-11-15